Related Experiment Video
Updated: May 5, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C Virus: An Overview of Its Chronic Impact on Liver Function, Metabolic Dysregulation,
Joana Ferreira1,2,3, João Caldeira2, Manuel Bicho1,3
1Institute for Scientific Research Bento Rocha Cabral, 1250-047 Lisbon, Portugal.
Insights
Hepatitis C virus (HCV) infection impacts millions, causing liver damage and metabolic issues. Direct-acting antivirals (DAAs) effectively cure HCV, improving liver health and metabolic function, but long-term monitoring is crucial.
Area of Science:
- Hepatology
- Virology
- Metabolic Medicine
Background:
- Hepatitis C virus (HCV) is a global health issue affecting over 71 million people.
- HCV infection leads to chronic liver disease, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
- HCV disrupts iron, lipid, and glucose metabolism, contributing to oxidative stress, steatosis, and type 2 diabetes.
Purpose of the Study:
- To review the systemic complications of HCV infection.
- To highlight the impact of direct-acting antivirals (DAAs) on HCV cure and metabolic outcomes.
- To emphasize the need for continued monitoring post-HCV cure.
Main Methods:
- Literature review of HCV pathogenesis and treatment.
- Analysis of HCV's effects on host metabolism.
- Evaluation of DAA efficacy and long-term sequelae.
Main Results:
- DAAs achieve >95% cure rates for HCV, improving liver function and reversing fibrosis.
- DAAs normalize metabolic dysregulation, including iron overload, steatosis, and insulin resistance.
- HCV-induced oxidative stress and iron overload may persist post-cure, necessitating ongoing care.
Conclusions:
- HCV treatment with DAAs significantly improves patient outcomes and metabolic health.
- Patients with advanced liver damage post-SVR remain at risk for HCC and metabolic diseases.
- Personalized post-treatment care and monitoring are essential for managing long-term risks.
Abstract:
Hepatitis C virus (HCV) infection is a global health concern, chronically affecting over 71 million people. It primarily targets the liver but also causes systemic complications through inflammation, oxidative stress, and metabolic dysregulation. HCV is a highly variable RNA virus with six major genotypes that are mainly transmitted via blood. Often asymptomatic, the infection progresses silently to chronic hepatitis C (CHC), which can lead to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Direct-acting antivirals (DAAs) have revolutionized treatment, achieving cure rates above 95%, improving liver function, reversing fibrosis, and normalizing metabolism. HCV disrupts iron metabolism by suppressing hepcidin, causing iron overload and oxidative stress. It also alters lipid metabolism, inducing steatosis, and affects glucose metabolism, contributing to insulin resistance and type 2 diabetes. DAAs improve these metabolic outcomes. HCV promotes oxidative stress via viral proteins, damaging liver cells and DNA and triggering inflammation and fibrogenesis. Even post-cure, oxidative stress and iron overload may continue to drive disease progression. Genetic and epigenetic factors influence fibrosis progression and HCC risk. Despite a sustained virologic response (SVR), patients with advanced liver damage remain at risk for HCC and metabolic diseases, highlighting the need for continued monitoring and personalized post-treatment care.
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction
01:24Cirrhosis II: Pathophysiology
01:23Cirrhosis I: Introduction
01:21Chronic Pancreatitis II: Pathophysiology
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...